Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 4.11
NAS:SCYX's Cash-to-Debt is ranked higher than
52% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. NAS:SCYX: 4.11 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SCYX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 4.11 Max: No Debt
Current: 4.11
Equity-to-Asset 0.58
NAS:SCYX's Equity-to-Asset is ranked lower than
59% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:SCYX: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SCYX' s Equity-to-Asset Range Over the Past 10 Years
Min: -8.73  Med: 0.58 Max: 0.85
Current: 0.58
-8.73
0.85
Piotroski F-Score: 3
Altman Z-Score: -3.04
Beneish M-Score: -3.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -10866.02
NAS:SCYX's Operating Margin % is ranked lower than
97% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. NAS:SCYX: -10866.02 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SCYX' s Operating Margin % Range Over the Past 10 Years
Min: -10866.02  Med: -46.23 Max: 11030.74
Current: -10866.02
-10866.02
11030.74
Net Margin % -11714.45
NAS:SCYX's Net Margin % is ranked lower than
97% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. NAS:SCYX: -11714.45 )
Ranked among companies with meaningful Net Margin % only.
NAS:SCYX' s Net Margin % Range Over the Past 10 Years
Min: -12693.77  Med: -337.1 Max: -68.17
Current: -11714.45
-12693.77
-68.17
ROE % -79.39
NAS:SCYX's ROE % is ranked lower than
91% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. NAS:SCYX: -79.39 )
Ranked among companies with meaningful ROE % only.
NAS:SCYX' s ROE % Range Over the Past 10 Years
Min: -86.56  Med: -82.35 Max: -78.13
Current: -79.39
-86.56
-78.13
ROA % -56.74
NAS:SCYX's ROA % is ranked lower than
90% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. NAS:SCYX: -56.74 )
Ranked among companies with meaningful ROA % only.
NAS:SCYX' s ROA % Range Over the Past 10 Years
Min: -248.61  Med: -73.36 Max: -16.27
Current: -56.74
-248.61
-16.27
GuruFocus has detected 4 Warning Signs with SCYNEXIS Inc $NAS:SCYX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SCYX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NAS:SCYX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:SENZ, OTCPK:WUYIF, OTCPK:MGCLF, NAS:MEIP, NAS:PSDV, NAS:LPCN, OTCPK:MGWFF, NAS:IMMY, NAS:GALT, NAS:BPTH, NAS:JNP, OTCPK:MRPHF, OTCPK:BIOYF, NAS:EVOK, OTCPK:NRIFF, NAS:SPHS, OTCPK:CPHRF, NAS:EPIX, OTCPK:ZOMHF, NAS:AGRX » details
Traded in other countries:135.Germany,
Headquarter Location:USA
SCYNEXIS Inc is a pharmaceutical company engaged in the discovery, development, and commercialization of novel anti-infectives to address unmet therapeutic needs.

SCYNEXIS Inc was incorporated in Delaware in November 4, 1999 as ScyRex, Inc. In June 2002, the Company changed its name to SCYNEXIS Inc. It is a pharmaceutical company engaged in the discovery, development, and commercialization of novel anti-infectives to address unmet therapeutic needs. The Company is developing its product candidate SCY-078, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, it has a clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases. It also provides contract research and development services in the field of animal health. The Company's competitors include pharmaceutical and biotechnology companies, and specialty pharmaceutical and generic drug companies.

Top Ranked Articles about SCYNEXIS Inc

SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID
SCYX LOSS NOTICE: Rosen Law Firm Reminds SCYNEXIS, Inc. Investors of Important Deadline in Class Action – SCYX
The Klein Law Firm Announces the Commencement of a Class Action Filed on Behalf of SCYNEXIS, Inc. Shareholders and a Lead Plaintiff Deadline of May 8, 2017 (SCYX)
SCYX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving SCYNEXIS, Inc. and a Lead Plaintiff Deadline of May 8, 2017
SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against SCYNEXIS, Inc. (SCYX) & Lead Plaintiff Deadline - May 8, 2017
SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Encourages Investors with Losses to Contact the Firm
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In SCYNEXIS, Inc. (SCYX) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Encourages Investors with Losses to Contact the Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in SCYNEXIS, Inc. of Class Action Lawsuit and Upcoming Deadline – SCYX

NEW YORK, March 24, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against SCYNEXIS, Inc. (“Scynexis” or the “Company”) (NASDAQ:SCYX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 17-cv-01565, is on behalf of a class consisting of investors who purchased or otherwise acquired Scynexis securities: (1) pursuant and/or traceable to Scynexis’ false and misleading Registration Statement and Prospectus, issued in connection with the Company’s initial public offering on or about May 2, 2014 (the “IPO” or the “Offering”); and/or (2) on the open market between May 2, 2014 and March 2, 2017, both dates inclusive (the “Class Period”), seeking to recover damages caused by defendants’ violations of the Securities Act of 1933 (the “Securities Act”) and the Securities Exchange Act of 1934 (the “Exchange Act”). If you are a shareholder who purchased Scynexis securities between May 2, 2014 and March 2, 2017, both dates inclusive, you have until May 8, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. [Click here to join this class action] Scynexis, Inc. is a pharmaceutical company that develops and distributes intravenous drugs for the treatment of serious and life-threatening invasive fungal infections in humans. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Scynexis’s lead product SCY-078 entailed substantial undisclosed health and safety risks; (ii) consequently, the Company had overstated the drug’s approval prospectus and/or commercial viability; and (iii) as a result of the foregoing, Scynexis’s public statements were materially false and misleading at all relevant times. On March 2, 2017, post-market, Scynexis issued a press release, attached as Exhibit 99.1 on Form 8-K, entitled “Scynexis delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request,” announcing the FDA’s clinical hold on clinical trials for the intravenous formulation of the Company's lead product candidate SCY-078. The Company stated that “[t]he clinical hold decision was issued by the FDA following a review of three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of SCY-078 at the highest doses and highest concentrations in a Phase 1 study.”  On this news, Scynexis’s share price fell $0.57, or 17.43%, to close at $2.70 on March 3, 2017. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.82
SCYX's PB Ratio is ranked higher than
67% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. SCYX: 1.82 )
Ranked among companies with meaningful PB Ratio only.
SCYX' s PB Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.95 Max: 3.5
Current: 1.82
1.08
3.5
PS Ratio 171.33
SCYX's PS Ratio is ranked lower than
97% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. SCYX: 171.33 )
Ranked among companies with meaningful PS Ratio only.
SCYX' s PS Ratio Range Over the Past 10 Years
Min: 0.42  Med: 46.18 Max: 303.91
Current: 171.33
0.42
303.91
EV-to-EBIT -0.88
SCYX's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. SCYX: -0.88 )
Ranked among companies with meaningful EV-to-EBIT only.
SCYX' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.3  Med: -0.7 Max: 3
Current: -0.88
-7.3
3
EV-to-EBITDA -0.88
SCYX's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. SCYX: -0.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
SCYX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.2  Med: -0.7 Max: 3
Current: -0.88
-9.2
3
Current Ratio 15.96
SCYX's Current Ratio is ranked higher than
96% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. SCYX: 15.96 )
Ranked among companies with meaningful Current Ratio only.
SCYX' s Current Ratio Range Over the Past 10 Years
Min: 0.16  Med: 7.27 Max: 15.96
Current: 15.96
0.16
15.96
Quick Ratio 15.96
SCYX's Quick Ratio is ranked higher than
96% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. SCYX: 15.96 )
Ranked among companies with meaningful Quick Ratio only.
SCYX' s Quick Ratio Range Over the Past 10 Years
Min: 0.16  Med: 7.27 Max: 15.96
Current: 15.96
0.16
15.96
Days Sales Outstanding 332.21
SCYX's Days Sales Outstanding is ranked lower than
97% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. SCYX: 332.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCYX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.57  Med: 65.68 Max: 1320.82
Current: 332.21
15.57
1320.82

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.88
SCYX's Price-to-Net-Cash is ranked higher than
94% of the 206 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.25 vs. SCYX: 1.88 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SCYX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.88  Med: 2.33 Max: 3.26
Current: 1.88
1.88
3.26
Price-to-Net-Current-Asset-Value 1.84
SCYX's Price-to-Net-Current-Asset-Value is ranked higher than
91% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. SCYX: 1.84 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SCYX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.84  Med: 2.28 Max: 2.54
Current: 1.84
1.84
2.54
Price-to-Tangible-Book 1.82
SCYX's Price-to-Tangible-Book is ranked higher than
73% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. SCYX: 1.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SCYX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.82  Med: 2.25 Max: 2.54
Current: 1.82
1.82
2.54
Price-to-Median-PS-Value 3.72
SCYX's Price-to-Median-PS-Value is ranked lower than
93% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. SCYX: 3.72 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SCYX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.29  Med: 4.62 Max: 5.86
Current: 3.72
0.29
5.86
Earnings Yield (Greenblatt) % -113.64
SCYX's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. SCYX: -113.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SCYX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -113.64  Med: 135.55 Max: 8156.7
Current: -113.64
-113.64
8156.7

More Statistics

Revenue (TTM) (Mil) $0.26
EPS (TTM) $ -1.61
Short Percentage of Float8.25%
52-Week Range $1.74 - 5.51
Shares Outstanding (Mil)25.53

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.73 -2.16 -2.16
EPS without NRI ($) -1.73 -2.16 -2.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:SCYX

Headlines

Articles On GuruFocus.com
SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented a Apr 21 2017 
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,0 Apr 20 2017 
SCYX LOSS NOTICE: Rosen Law Firm Reminds SCYNEXIS, Inc. Investors of Important Deadline in Class Act Apr 14 2017 
The Klein Law Firm Announces the Commencement of a Class Action Filed on Behalf of SCYNEXIS, Inc. Sh Apr 14 2017 
SCYX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving S Apr 13 2017 
SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Apr 12 2017 
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against SCY Apr 06 2017 
SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, In Apr 03 2017 
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Inve Apr 03 2017 
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against SCYNEXI Mar 31 2017 

More From Other Websites
SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented... Apr 21 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and... Apr 20 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Apr 20 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of Commencement of a... Apr 20 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Apr 20 2017
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SCYNEXIS, Inc. of Commencement of a... Apr 19 2017
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc.... Apr 14 2017
SCYX LOSS NOTICE: Rosen Law Firm Reminds SCYNEXIS, Inc. Investors of Important Deadline in Class... Apr 14 2017
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And... Apr 14 2017
The Klein Law Firm Announces the Commencement of a Class Action Filed on Behalf of SCYNEXIS, Inc.... Apr 14 2017
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of SCYNEXIS, Inc. and Encourages... Apr 13 2017
SCYX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Apr 13 2017
SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of... Apr 12 2017
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against SCYNEXIS, Inc.... Apr 10 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SCYNEXIS, Inc. of a Class Action... Apr 10 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Apr 07 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Apr 07 2017
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against SCYNEXIS,... Apr 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)